Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAMROCK: Neoadjuvant T-DXd in HER2+ Breast Cancer
NCT05710666Phase 2Active, not recruiting
- Sponsor
- Cancer Trials Ireland
- Start
- Oct 2023
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by Cancer Trials Ireland. Started Oct 2023; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05710666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05710666.